Previous close | 0.5700 |
Open | 0.5700 |
Bid | 0.0000 |
Ask | 5.0000 |
Strike | 40.00 |
Expiry date | 2024-07-19 |
Day's range | 0.5700 - 0.5700 |
Contract range | N/A |
Volume | |
Open interest | 2 |
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today the launch of its Xenium Prime 5K Pan-Tissue and Pathways panel. The new assay features an enhanced chemistry to increase plex by an order of magnitude while delivering excellent per-gene sensitivity, improved specificity and spatial fidelity, integrated multimodal cell segmentation, and industry-leading speed and throughput.
Review 10x Genomics' (TXG) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that members of its management team will participate in a fireside chat at the BofA Securities 2024 Healthcare Conference on Tuesday, May 14, at 4:20 p.m. Pacific Time.